Final results of randomized study of gemcitabine (G) plus cisplatin (P) versus etoposide (E) plus cisplatin in locally advanced or metastatic non small cell lung cancer (NSCLC)

被引：0
|
作者：
Bousahba, A., Sr. [1 ]
Bereksi-Reguig, F. [1 ]
Seghier, F. [1 ]
Boukerche, A. [1 ]
Dali-Youcef, A. [1 ]
Djellali, L. [1 ]
机构：
[1] Natl Inst Med, Oran, Algeria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.19006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19006
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabin (G) plus cisplatin (P) versus etoposid (E) plus cisplatin in advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a randomized monocentric study
    Bousahba, A.
    Bereksi-Reguig, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience
    Kim, JH
    Kim, SY
    Jung, KH
    Park, K
    Suh, CW
    Lim, HY
    Kim, YH
    Ryoo, BY
    Cho, EK
    Park, BJ
    Heo, DS
    [J]. LUNG CANCER, 2006, 52 (01) : 75 - 81
  • [3] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
  • [4] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Manegold, C.
    Digumarti, R.
    Zukin, M.
    de Marinis, F.
    Mellerngaard, A.
    Gandara, D.
    Simms, L.
    Kaiser, C.
    Blatter, J.
    Gatzemeier, U.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 9 - 9
  • [5] Cost-effectiveness of Gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain
    Rosell, R
    Sacristan, JA
    Duthie, T
    Cardenal, F
    Artal, A
    Carrato, A
    Lomas, M
    Barneto, I
    Bameto, I
    Massuti, B
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 92 - 93
  • [6] Gemcitabine plus cisplatin in advanced non small cell lung cancer (NSCLC)
    Casal, J
    Huidobro, G
    Grande, C
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 103 - 103
  • [7] A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer
    Goksel, T
    Hatipoglu, ON
    Ozturk, C
    Gorguner, M
    Kiyik, M
    Yilmaz, U
    Guzelant, A
    Tasbakan, S
    Tabakoglu, E
    Firat, H
    Tutar, U
    Cikrikicioglu, S
    Akkoclu, A
    Soyer, S
    Cakir, E
    Itil, O
    Sanal, S
    [J]. RESPIROLOGY, 2005, 10 (04) : 456 - 463
  • [8] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [9] A randomized study of gemcitabine monotherapy versus Etoposide/Cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
    Manegold, C
    Drings, P
    vonPawel, J
    Ricci, S
    Dornoff, W
    vanWalree, N
    Huinink, WT
    Chemaissani, A
    Stahel, P
    Bergman, B
    Wagenius, G
    Sederholm, C
    Mattson, K
    Liippo, K
    KellokumpuLehtinen, P
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (03) : 813 - 817
  • [10] Gemcitabine (G) plus cisplatin (C) in advanced non-small cell lung cancer (NSCLC): Final phase II results.
    Casal, J
    Huidobro, G
    Grande, C
    Caeiro, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
12345